In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include:

Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signaling
Preclinical PK, PD, MOA and combination with PD-1 checkpoint inhibition
Clinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancer
Combinations under investigation

To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

Share

Embed